HL-60—derived cell line data
. | Expression, mean ± SD (no. independent assays) . | . | . | . | Efflux, mean ± SD (no. independent assays) . | . | Toxicity, mean % ± SD (no. independent assays) . | . | . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cell line . | CD33 . | pBzR . | Pgp . | MRP1 . | DiOC2 + CSA . | CDCF + MK571 . | GO − untrtd . | GO + PK − PK only . | GO + CSA − CSA only . | GO + MK − MK only . | |||||||
| HL-60/AR | 26 ± 7 (4) | 3765 ± 761 (3) | 0.9 ± 0.1 (6) | 4.5 ± 2.9 (6) | 1.2 ± 0 (4) | 24.6 ± 3.0 (6) | − 6 ± 3 (4) | − 15 ± 1 | − 9 ± 1 | − 5 ± 2 | |||||||
| P | — | — | — | — | — | — | < .001* | < .0001†, < .05# | NS, NS | NS, NS | |||||||
| HL-60/VCR | 116 ± 46 (4) | 2287 ± 661 (3) | 5.5 ± 1.0 (4) | 1.9 ± 0.1 (5) | 274 ± 40 (4) | 22.3 ± 6.5 (4) | − 3 ± 1 (3) | − 3 ± 2 | − 2 ± 2 | − 2 ± 2 | |||||||
| P | — | — | — | — | — | — | < .05* | NS, NS | NS, NS | NS, NS | |||||||
| HL-60/Bcl-2 | 65 ± 24 (3) | 728 ± 539 | 0.8 ± 0.2 (3) | 1.5 ± 0.2 (3) | 1.0 ± 0 (3) | 18.2 ± 9.1 (3) | − 15 ± 1 (2) | − 34 ± 4 | − 32 ± 1 | nd | |||||||
| P | — | — | — | — | — | — | < .01* | < .01†, < .01‡ | < .001†, < .001‡ | — | |||||||
| HL-60/Bcl-xL | 69 ± 21 (3) | 6 ± 34 | 0.8 ± 0.1 (3) | 1.5 ± 0.2 (3) | 1.0 ± 0 (3) | 10.7 ± 2.8 (3) | − 16 ± 2 (2) | − 54 ± 4 | − 37 ± 1 | nd | |||||||
| P | — | — | — | — | — | — | < .01* | < .0001†, < .0001‡ | < .0001†, < .0001‡ | — | |||||||
. | Expression, mean ± SD (no. independent assays) . | . | . | . | Efflux, mean ± SD (no. independent assays) . | . | Toxicity, mean % ± SD (no. independent assays) . | . | . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cell line . | CD33 . | pBzR . | Pgp . | MRP1 . | DiOC2 + CSA . | CDCF + MK571 . | GO − untrtd . | GO + PK − PK only . | GO + CSA − CSA only . | GO + MK − MK only . | |||||||
| HL-60/AR | 26 ± 7 (4) | 3765 ± 761 (3) | 0.9 ± 0.1 (6) | 4.5 ± 2.9 (6) | 1.2 ± 0 (4) | 24.6 ± 3.0 (6) | − 6 ± 3 (4) | − 15 ± 1 | − 9 ± 1 | − 5 ± 2 | |||||||
| P | — | — | — | — | — | — | < .001* | < .0001†, < .05# | NS, NS | NS, NS | |||||||
| HL-60/VCR | 116 ± 46 (4) | 2287 ± 661 (3) | 5.5 ± 1.0 (4) | 1.9 ± 0.1 (5) | 274 ± 40 (4) | 22.3 ± 6.5 (4) | − 3 ± 1 (3) | − 3 ± 2 | − 2 ± 2 | − 2 ± 2 | |||||||
| P | — | — | — | — | — | — | < .05* | NS, NS | NS, NS | NS, NS | |||||||
| HL-60/Bcl-2 | 65 ± 24 (3) | 728 ± 539 | 0.8 ± 0.2 (3) | 1.5 ± 0.2 (3) | 1.0 ± 0 (3) | 18.2 ± 9.1 (3) | − 15 ± 1 (2) | − 34 ± 4 | − 32 ± 1 | nd | |||||||
| P | — | — | — | — | — | — | < .01* | < .01†, < .01‡ | < .001†, < .001‡ | — | |||||||
| HL-60/Bcl-xL | 69 ± 21 (3) | 6 ± 34 | 0.8 ± 0.1 (3) | 1.5 ± 0.2 (3) | 1.0 ± 0 (3) | 10.7 ± 2.8 (3) | − 16 ± 2 (2) | − 54 ± 4 | − 37 ± 1 | nd | |||||||
| P | — | — | — | — | — | — | < .01* | < .0001†, < .0001‡ | < .0001†, < .0001‡ | — | |||||||
Data were collected and are presented as in Table 1. Additional cytotoxicity data for these cell lines also are presented in Figures 3 and 4. HL-60/AR refers to MRP + + cells and HL-60/VCR to Pgp + + cells. Untrtd indicates untreated; —, not calculated; NS, not significant (ie, P ≥ .05 compared to treatment with GO or sensitizer only); nd, not done.
Compared to viability of untreated cells.
Compared to cells treated with GO only.
Compared to treatment with sensitizer alone.